---
title: "Calcitonin Salmon"
canonical_url: https://peptidelibrary.app/library/calcitonin-salmon
description: "Synthetic 32-amino-acid polypeptide identical to salmon calcitonin, approved for Paget disease of bone, hypercalcaemia, and postmenopausal osteoporosis in women more than five years past menopause."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Calcitonin Salmon

Calcitonin Salmon is an FDA-approved calcitonin receptor agonist. Calcitonin binds the calcitonin receptor on osteoclasts, producing rapid loss of the ruffled border and reduced bone resorption, and acts at the renal tubule to increase calcium excretion. The salmon sequence binds the human receptor with higher affinity and is cleared more slowly than human calcitonin, which is why the salmon form is the one used clinically.

Synthetic 32-amino-acid polypeptide identical to salmon calcitonin, approved for Paget disease of bone, hypercalcaemia, and postmenopausal osteoporosis in women more than five years past menopause.

Categories: Longevity.

## Classification

- Type: FDA-approved calcitonin receptor agonist
- Mechanism class: Calcitonin Receptor Agonist
- Development stage: Approved product
- Regulatory class: FDA-approved medicine

## Mechanism

Calcitonin binds the calcitonin receptor on osteoclasts, producing rapid loss of the ruffled border and reduced bone resorption, and acts at the renal tubule to increase calcium excretion. The salmon sequence binds the human receptor with higher affinity and is cleared more slowly than human calcitonin, which is why the salmon form is the one used clinically.

## Properties

- Molecular formula: C145H240N44O48S2
- Molecular weight: 3,431.9 g/mol
- Studied routes: Subcutaneous, Intramuscular, Intranasal

## Evidence

- Evidence level: FDA Approved
- Highest documented: Regulatory review (FDA label)
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 0

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. MIACALCIN (calcitonin salmon) injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Adults with symptomatic Paget's disease of bone when alternative treatments are not suitable. Treatment of Paget's disease [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26caf31f-7f7c-48a8-a1ac-35d2ceefda2b)
2. MIACALCIN (calcitonin salmon) injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Patients with hypercalcemia. Lower serum calcium [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26caf31f-7f7c-48a8-a1ac-35d2ceefda2b)
3. MIACALCIN (calcitonin salmon) injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Women more than 5 years past menopause with osteoporosis when alternative treatments are not suitable. Treatment of postmenopausal osteoporosis; fracture reduction not demonstrated [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26caf31f-7f7c-48a8-a1ac-35d2ceefda2b)
4. Calcitonin salmon nasal spray (Apotex) — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Women more than 5 years past menopause with osteoporosis when alternative treatments are not suitable. Treatment of postmenopausal osteoporosis; fracture reduction not demonstrated [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c82eb602-12e1-692b-d660-f8d5b5736b54)

## Safety

Human safety basis: FDA prescribing information

## Regulatory status

Calcitonin Salmon is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

- FDA status: Approved
- Availability: Prescription-Only

## Frequently asked questions

### What is Calcitonin Salmon?

Synthetic 32-amino-acid polypeptide identical to salmon calcitonin, approved for Paget disease of bone, hypercalcaemia, and postmenopausal osteoporosis in women more than five years past menopause.

### How does Calcitonin Salmon work?

Calcitonin binds the calcitonin receptor on osteoclasts, producing rapid loss of the ruffled border and reduced bone resorption, and acts at the renal tubule to increase calcium excretion. The salmon sequence binds the human receptor with higher affinity and is cleared more slowly than human calcitonin, which is why the salmon form is the one used clinically.

### Is Calcitonin Salmon FDA approved?

Yes. Calcitonin Salmon is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

### What peptides are similar to Calcitonin Salmon?

Compounds most often compared with Calcitonin Salmon include Elamipretide (SS-31) and Methylene Blue. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes — Drugs, 2015](https://pubmed.ncbi.nlm.nih.gov/25822610/)
- [\[The preliminary results of research on salcatonin treatment in the surgical therapy of jaw cysts\] — Minerva Stomatol, 1991](https://pubmed.ncbi.nlm.nih.gov/1753937/)
- [Effect of salcatonin given intranasally on early postmenopausal bone loss — BMJ, 1989](https://pubmed.ncbi.nlm.nih.gov/2507027/)
- [Calcitonin intranasal--unigene: Salcatonin intranasal--unigene — Drugs R D, 2004](https://pubmed.ncbi.nlm.nih.gov/15293868/)
- [Calcitonin (FORTICAL, MIACALCIN) for the treatment of vertebral compression fractures — Orthop Rev (Pavia), 2021](https://pubmed.ncbi.nlm.nih.gov/34745472/)
